While the much-talked-about patent cliff won't hit until 2011, 2010 will still see patent expirations of some of the industry's blockbuster drugs. Teva, Apotex, Mylan and a slew of other generic drugmakers will have a chance to put a dent in the sales of a number of brand meds this year--including Flomax and Aricept. Lipitor, whose basic patent expires this year, doesn't face competition until 2011 because of Pfizer's deal with Ranbaxy, the first-filer. It's still included in the following list, which has a number of top-selling drugs.
Our 2010 patent expiration list also includes drugs whose patent actually expires, but managed to get a six-month extension due to pediatric exclusivity. Report [1]
1. Cozaar/Hyzaar [1] - Merck
2. Lipitor [2]- Pfizer
3. Flomax [3]- Boehringer Ingelheim
4. Arimidex [4]- AstraZeneca
5. Climara [5] - Bayer HealthCare
6. Aricept [6]- Aricept
7. Invirase [7] - Roche
8. Hycamtin [8] - GlaxoSmithKline
9. Protonix [9]- Pfizer
10. Levaquin [10] - Levaquin
Links:
[1] http://www.fiercepharma.com/special-reports/cozaar-hyzaar-big-patentexpirations-2010
[2] http://www.fiercepharma.com/special-reports/lipitor
[3] http://www.fiercepharma.com/special-reports/flomax-big-patent-expirations-2010
[4] http://www.fiercepharma.com/special-reports/arimidex-big-patent-expirations-2010
[5] http://www.fiercepharma.com/special-reports/climara-big-patent-expirations-2010
[6] http://www.fiercepharma.com/special-reports/aricept-big-patent-expirations-2010
[7] http://www.fiercepharma.com/special-reports/invirase-big-patent-expirations-2010
[8] http://www.fiercepharma.com/special-reports/hycamtin-big-patent-expirations-2010
[9] http://www.fiercepharma.com/special-reports/protonix-big-patent-expirations-2010
[10] http://www.fiercepharma.com/special-reports/levaquin-big-patent-expirations-2010